Kala Pharmaceuticals

OverviewSuggest Edit

Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Kala’s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation, dry eye disease, and meibomian gland disease.

Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD). Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.

TypePublic
Founded2009
HQWatertown, MA, US
Websitekalarx.com
Overall CultureA+

Latest Updates

Employees (est.) (Feb 2019)37(+48%)
Revenue (FY, 2015)$45 K
Share Price (Jan 2021)$7.5
Cybersecurity ratingBMore

Key People/Management at Kala Pharmaceuticals

Mark Iwicki

Mark Iwicki

Chairman and Chief Executive Officer
Kim Brazzell

Kim Brazzell

Chief Medical Officer
Howard B. Rosen

Howard B. Rosen

Director
Hongming Chen

Hongming Chen

Chief Scientific Officer
Gregory Grunberg

Gregory Grunberg

Director
Mary Reumuth

Mary Reumuth

Chief Financial Officer
Show more

Kala Pharmaceuticals Office Locations

Kala Pharmaceuticals has offices in Watertown and Waltham
Watertown, MA, US (HQ)
490 Arsenal Way #120Watertown
Waltham, MA, US
100 Beaver St #201
Show all (2)

Kala Pharmaceuticals Financials and Metrics

Kala Pharmaceuticals Revenue

Kala Pharmaceuticals's revenue was reported to be $45 k in FY, 2015
USD

Net income (FY, 2016)

(33.2m)

EBIT (FY, 2016)

(32.7m)

Market capitalization (15-Jan-2021)

420.0m

Closing stock price (15-Jan-2021)

7.5

Cash (31-Dec-2016)

42.5m
Kala Pharmaceuticals's current market capitalization is $420 m.
USDFY, 2015FY, 2016

Revenue

45.0k

General and administrative expense

4.6m7.6m

R&D expense

11.4m25.0m

Operating expense total

16.0m32.7m
USDFY, 2015FY, 2016

Cash

5.8m42.5m

Current Assets

7.6m45.6m

PP&E

738.0k594.0k

Total Assets

8.4m46.3m
USDFY, 2015FY, 2016

Net Income

(16.7m)(33.2m)

Depreciation and Amortization

330.0k297.0k

Accounts Payable

911.0(343.0)

Cash From Operating Activities

(15.1m)(27.3m)
Show all financial metrics

Kala Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

101

Patents (Foreign)

2

Patents (US)

6
Show all operating metrics

Kala Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Kala Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Kala Pharmaceuticals Online and Social Media Presence

Embed Graph

Kala Pharmaceuticals Company Culture

  • Overall Culture

    A+

    94/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Kala Pharmaceuticals News and Updates

Kala Pharmaceuticals Blogs

Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline kevindavis Thu, 01/07/2021 - 07:02 Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on De…

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

WATERTOWN, Mass. --(BUSINESS WIRE)--Jan. 4, 2021-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences

Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease

-- Poster presentation and promotional activities highlighted at the American Academy of Ophthalmology 2020 Virtual Annual Meeting -- -- On-track to begin shipping EYSUVIS to wholesalers in mid-December -- -- Wholesale Acquisition Cost announced -- WATERTOWN, Mass. --(BUSINESS WIRE)--Nov.

Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference

WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 11, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2020 Virtual

Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Content Import Thu, 11/05/2020 - 07:01 Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update November 5, 2020 at 7:00 AM EST …

Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call

WATERTOWN, Mass. --(BUSINESS WIRE)--Oct. 29, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial
Show more

Kala Pharmaceuticals Frequently Asked Questions

  • When was Kala Pharmaceuticals founded?

    Kala Pharmaceuticals was founded in 2009.

  • Who are Kala Pharmaceuticals key executives?

    Kala Pharmaceuticals's key executives are Mark Iwicki, Kim Brazzell and Howard B. Rosen.

  • How many employees does Kala Pharmaceuticals have?

    Kala Pharmaceuticals has 37 employees.

  • Who are Kala Pharmaceuticals competitors?

    Competitors of Kala Pharmaceuticals include GT Biopharma, PTC Therapeutics and Pulmatrix.

  • Where is Kala Pharmaceuticals headquarters?

    Kala Pharmaceuticals headquarters is located at 490 Arsenal Way #120Watertown, Watertown.

  • Where are Kala Pharmaceuticals offices?

    Kala Pharmaceuticals has offices in Watertown and Waltham.

  • How many offices does Kala Pharmaceuticals have?

    Kala Pharmaceuticals has 2 offices.